Skip to main content
Premium Trial:

Request an Annual Quote

People in the News: Cheryl Moore, Hilde Windels, and more

Cheryl Moore

The New York Genome Center (NYGC) has appointed Cheryl Moore as president and COO. She will assume the position in January. Moore will be responsible for all business functions of NYGC, reporting to and partnering with Robert Darnell to set overall strategic direction and make key business decisions for the organizations.

Moore comes to NYGC after five years as the executive vice president and COO of the Howard Hughes Medical Institute (HHMI), where she has led collaborative strategic efforts and oversees key operational functions. From 2004 to 2010, she served as COO of HHMI's Janelia Research Campus, where she was responsible for all operational aspects of the campus and its $100 million budget. Prior to HHMI, Moores erved as senior vice president and COO of the Sanford Burnham Prebys Medical Discovery Institute. 

Hilde Windels, Ewoud Welton 

Biocartis named Hilden Windels its deputy CEO and Ewoud Welton its CFO. Windels had been the firm's CFO. In his new position, he will continue to work closely with Biocartis CEO Rudi Pauwels. Welton joins the company from investment bank Kempen & Co. He has extensive experience in the healthcare sector as a corporate financier. 

Kenneth Weg, Shawn Marcell 

Metamark Genetics has appointed Kenneth Weg as president and CEO. He succeeds Shawn Marcell, who resigned from his position to pursue other activities. Weg is a Metamark co-founder and current chairman of the board of directors. He has previously served as the president of the Worldwide Medicines Group at Bristol-Myers Squibb (BMS), where he was responsible for overseeing all ethical pharmaceuticals and over-the-counter medicines on a global basis. Weg also served as vice chairman of the BMS board of directors. Before his work at BMS, he held the position of non-executive chairman of Millennium Pharmaceuticals. He has also served on the boards of Fox Chase Cancer Center and AVEO Pharmaceuticals and is a current member of Karyopharm's board of directors. 

Tim Barabe

Former Affymetrix CFO Tim Barabe has joined the board of Veeva Systems, a provider of industry cloud solutions for the life sciences. In addition to his role at Affymetrix, Barabe was a senior vice president and CFO at Human Genome Sciences. He also held senior international executive roles in finance, general management, and strategic planning at Novartis.  

For more recent items on executive appointments and promotions in the omics and molecular diagnostics industries, please see the People in the News page on our website.

The Scan

Topical Compound to Block EGFR Inhibitors May Ease Skin Toxicities, Study Finds

A topical treatment described in Science Translational Medicine may limit skin toxicities seen with EGFR inhibitor therapy.

Dozen Genetic Loci Linked to Preeclampsia Risk in New GWAS

An analysis of genome-wide association study data in JAMA Cardiology finds genetic loci linked to preeclampsia that have ties to blood pressure.

Cancer Survival Linked to Mutational Burden in Pan-Cancer Analysis

A pan-cancer paper appearing in JCO Precision Oncology suggests tumor mutation patterns provide clues for predicting cancer survival that are independent of other prognostic factors.

Australian Survey Points to Public Support for Genetic Risk Disclosure in Relatives of At-Risk Individuals

A survey in the European Journal of Human Genetics suggests most adult Australians are in favor of finding out if a relative tests positive for a medically actionable genetic variant.